Today's Date: March 26, 2023
AI-Powered Stylitics Launches Latest Platform with First-of-Its-Kind Automated Styling Technology for Retailers   •   HYZON MOTORS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers   •   Early Education Leadership Conference in Hershey Brings Together Hundreds of Child Advocates   •   30+ Health Leaders Explore Strategies to Ease Hospital-to-Home Patient Transitions   •   DISH ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against DISH Network Corporatio   •   ARGO DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Argo B   •   Philadelphia Works Names First Female Chief Operating Officer   •   SAMARITAN'S PURSE RUSHING HELP TO FAMILIES IMPACTED BY DEADLY TORNADOES IN MISSISSIPPI   •   Jennifer S. Wilkov Finalizes Lineup for the 2023 April Speak Up Women Conference   •   Here Comes Bunnysaurus Rex Hopping Down the Dinosaur Trail   •   Atlanta Housing, Residents Celebrate 102nd Birthday of Clara "Mama" Bridges   •   SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Stanley Black & Decker, Inc. with Losses of $100,000 t   •   Build community with shared future, create better world   •   National University Receives 2023 Military Friendly® Gold Designation   •   ImmunoGen Presents Final Overall Survival and Additional Efficacy Data from the SORAYA Trial at SGO Annual Meeting   •   GINKGO BIOWORKS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Office   •   Statement from the Chief Public Health Officer of Canada on World TB Day   •   SOTERA HEALTH 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Los   •   Dr. Kelli Ward and Martha Boneta Fain join the advisory board of Legacy PAC, a partner of Veterans for Trump   •   SOTERA DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Sote
Bookmark and Share

Biological Dynamics launches ExoVita™ Pancreas and enrolls patients in ExoLuminate clinical trial

SAN DIEGO , February 08 /Businesswire/ - Biological Dynamics, Inc., a company commercializing its exosome-isolation ExoVerita™ platform for early disease surveillance and other applications, today announced completion of the analytical and clinical validation of its lab developed test (LDT), ExoVita™ Pancreas in the company’s CLIA certified and CAP accredited laboratory.

Using blood-based exosome samples enriched on the proprietary ExoVerita instrument, the ExoVita Pancreas assay measures specific exosomal protein biomarkers and has been demonstrated to detect Stage 1 and Stage 2 pancreatic ductal adenoma carcinoma (PDAC)1.

With this validation, samples from the ExoLuminate registry trial (NCT05625529), a trial which has already begun actively enrolling patients with high-risk for PDAC to investigate the test’s clinical utility, will be tested by the company. Eligible patients include those with a familial or genetic predisposition, an individual’s clinical symptoms such as pancreatitis or known pancreatic lesions, and newly diagnosed diabetics over the age of 50.

“Our published, high sensitivity ExoVita Pancreas assay for early-stage pancreatic cancer is being further validated with prospective clinical samples from our ExoLuminate registry trial. Further leveraging the unique power of our ExoVerita platform, we plan to address additional cancer indications soon,” said Harmeet Dhani, MD, MSc, Director of Medical Affairs at Biological Dynamics. “Our expertise in isolating information rich exosomes, coupled with the unique clinical validity demonstrations, will significantly improve patient care.”

1 - Hinestrosa, J.P., Kurzrock, R., Lewis, J.M. et al. Early-stage multi-cancer detection using an extracellular vesicle protein-based blood test. Commun Med 2, 29 (2022).

Disclaimer: Biological Dynamics does not provide diagnostic information. ExoVita Pancreas is a ‘Research Use Only’ (RUO) test produced from Biological Dynamics’ CAP/CLIA certified lab. Any and all clinical decision-making remains with each study patient participant and their physician providers.

About Biological Dynamics

Biological Dynamics, Inc. is committed to improving global health outcomes by detecting diseases at the earliest stages. The Company’s proprietary ExoVerita™ platform simplifies isolation of extracellular vesicles, enabling multiomic applications. Its PDAC assay (ExoVita Pancreas) operates in a College of American Pathologists (CAP) accredited, CLIA-certified clinical laboratory in San Diego. Biological Dynamics recently announced the initiation of the ExoLuminate study, a clinical trial to demonstrate effectiveness of early-stage detection of pancreatic cancer. Learn more at

STORY TAGS: Product/Service, United States, North America, Oncology, Health, Other Science, Clinical Trials, Research, Science, Biotechnology, California,


White House Live Stream
alsharpton Rev. Al Sharpton
9 to 11 am EST
jjackson Rev. Jesse Jackson
10 to noon CST


Sounds Make the News ®
Atlanta - WAOK-Urban
Berkley / San Francisco - KPFA-Progressive
Chicago - WVON-Urban
KJLH - Urban
Los Angeles - KJLH - Urban
WKDM-Mandarin Chinese
New York - WKDM-Mandarin Chinese
New York - WADO-Spanish
WBAI - Progressive
New York - WBAI - Progressive
Washington - WOL-Urban

Listen to United Natiosns News